Morgan Stanley analyst Michael Cyprys raised the firm’s price target on BlackRock (BLK) to $1,261 from $1,245 and keeps an Overweight rating on the shares. For the asset manager group ...

Recursion announced that the first patient has been dosed in its Phase 1/2 clinical trial of REC-1245, a new chemical entity for the treatment of biomarker-enriched solid tumors and lymphoma.

You are authorized to access and use the university’s trademarks for non-commercial purposes. You will comply with all posted policies, including our Trademark and Licensing Policy. We may suspend or ...